Patents by Inventor Takehiko Yamazaki

Takehiko Yamazaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210163552
    Abstract: A peptide which can be utilized as an active ingredient of a composition for use in stimulation of migration of PDGFR?-positive cells, a composition for use in recruitment of bone marrow mesenchymal stem cells from bone marrow to peripheral blood, a composition for use in regeneration of tissues, or a composition for use in stimulation of migration of bone marrow-derived stromal cells is provided.
    Type: Application
    Filed: April 24, 2018
    Publication date: June 3, 2021
    Applicants: SHIONOGI & CO., LTD., StemRIM Inc.
    Inventors: Yoichiro NIHASHI, Tomoyuki KAWACHI, Yukiko YAMATSU, Masataka FUMOTO, Takehiko YAMAZAKI
  • Publication number: 20210024594
    Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.
    Type: Application
    Filed: February 7, 2019
    Publication date: January 28, 2021
    Inventors: Katsuto TAMAI, Takashi SHIMBO, Takehiko YAMAZAKI
  • Publication number: 20200384074
    Abstract: The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing weight loss and an effect of suppressing shortening of the large intestine and mucosal damage in an animal model of inflammatory bowel diseases. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of inflammatory bowel diseases, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 10, 2020
    Inventors: Katsuto TAMAI, Takashi SHIMBO, Takehiko YAMAZAKI
  • Publication number: 20200369736
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Application
    Filed: December 13, 2019
    Publication date: November 26, 2020
    Inventors: KATSUTO TAMAI, TAKEHIKO YAMAZAKI, TSUTOMU KANEZAKI, SHIGERU SAKURAI, YUKIKO NOGUCHI, MAYUMI ENDO, NATSUMI HAMABUCHI, KANA NAITO
  • Publication number: 20200291359
    Abstract: The inventors discovered that ectodermal mesenchymal stem cells circulating in peripheral blood that are induced by necrotic tissue damage contribute to the regeneration of damaged tissue. On the basis of this discovery, provided are ectodermal mesenchymal stem cells, a method for producing the same, and a screening method for a substance having pluripotent stem cell inductive activity, the screening method using cells induced by necrotic tissue damage in peripheral blood as an index.
    Type: Application
    Filed: November 30, 2018
    Publication date: September 17, 2020
    Applicants: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto TAMAI, Takashi SHIMBO, Eiji SASAKI, Takehiko YAMAZAKI
  • Publication number: 20200038486
    Abstract: The present inventors discovered that an HMGB1 fragment peptide having a particular amino acid sequence exhibits effects of inhibiting finger adhesion and digestive tract scarring and prolonging survival in the dystrophic epidermolysis bullosa model mice. Also in the skin ulcer model, administration of the specific HMGB1 fragment peptide was found to inhibit the fibrosing of skin during the healing process of the ulcer. Based on these findings, the present application provides pharmaceutical compositions for the treatment of fibrotic diseases, which comprise the specific HMGB1 fragment peptide.
    Type: Application
    Filed: April 6, 2018
    Publication date: February 6, 2020
    Inventors: Katsuto TAMAI, Takahiro AOTO, Sho YAMAZAKI, Takehiko YAMAZAKI
  • Patent number: 10550165
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: February 4, 2020
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
  • Publication number: 20190358307
    Abstract: The purpose of the present invention is to provide a novel medicine that is effective in treating cerebral infarction. The present invention provides a pharmaceutical composition that contains a peptidyl-prolyl cis-trans isomerase B (PPIB) protein, a nucleic acid encoding the PPIB protein, or a cell that secretes the PPIB protein.
    Type: Application
    Filed: November 9, 2017
    Publication date: November 28, 2019
    Applicants: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto TAMAI, Takehiko YAMAZAKI, Koichi YOKOTA, Takahiro AOTO
  • Publication number: 20190343924
    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.
    Type: Application
    Filed: January 26, 2018
    Publication date: November 14, 2019
    Inventors: Katsuto TAMAI, Yoshiki SAWA, Shigeru MIYAGAWA, Takashi KIDO, Takasumi GOTO, Takehiko YAMAZAKI
  • Patent number: 10364276
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: July 30, 2019
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
  • Patent number: 10160792
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: December 25, 2018
    Assignees: STEMRIM INC., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Tsutomu Kanezaki, Shigeru Sakurai, Yukiko Noguchi, Mayumi Endo, Natsumi Hamabuchi, Kana Naito
  • Patent number: 9919010
    Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: March 20, 2018
    Assignees: GENOMIX CO., LTD., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Takenao Chino, Yasufumi Kaneda
  • Publication number: 20180072785
    Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.
    Type: Application
    Filed: August 30, 2017
    Publication date: March 15, 2018
    Inventors: KATSUTO TAMAI, TAKEHIKO YAMAZAKI, TSUTOMU KANEZAKI, SHIGERU SAKURAI, YUKIKO NOGUCHI, MAYUMI ENDO, NATSUMI HAMABUCHI, KANA NAITO
  • Publication number: 20180055886
    Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.
    Type: Application
    Filed: August 11, 2017
    Publication date: March 1, 2018
    Inventors: Katsuto TAMAI, Takehiko YAMAZAKI, Takenao CHINO, Yasufumi KANEDA
  • Patent number: 9688733
    Abstract: Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: June 27, 2017
    Assignees: GENOMIX CO., LTD., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Wenhao Cui
  • Patent number: 9623078
    Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: April 18, 2017
    Assignees: GENOMIX CO., LTD., OSAKA UNIVERSITY
    Inventors: Katsuto Tamai, Sokichi Kamata, Yasufumi Kaneda, Shigeru Miyagawa, Yoshiki Sawa, Takehiko Yamazaki
  • Patent number: 9346423
    Abstract: A control device for a vehicle includes: a motor generator mechanically connected to an output shaft of an engine; a main battery electrically connected to the motor generator; a sub battery electrically connected to an electric load of the vehicle; and a relay adapted to switch whether the batteries are to be electrically connected or not by turning the relay on or off. The relay is turned off during a powering operation of the motor generator, and the relay is turned on during a regenerative operation of the motor generator. It is determined that the relay is off-fixed in a case where a voltage of the second battery is a predetermined voltage or lower or a charge current of the second battery is a predetermined current or smaller in a state that a command to turn on the relay is outputted during the regenerative operation of the motor generator.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: May 24, 2016
    Assignee: NISSAN MOTOR CO., LTD.
    Inventor: Takehiko Yamazaki
  • Patent number: 9302671
    Abstract: A control device for a vehicle includes a relay adapted to switch whether a first battery electrically connected to a motor generator and a second battery electrically connected to an electric load of the vehicle are to be electrically connected or not by turning on/off the relay. The relay is turned off during a power operation of the motor generator to disconnect an electric connection between the first battery and the second battery. The relay is turned on during a regenerative operation of the motor generator to electrically connect the first battery and the second battery. In a case where an on-fixation failure of the relay is detected, the power operation of the motor generator is prohibited.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: April 5, 2016
    Assignee: NISSAN MOTOR CO., LTD.
    Inventor: Takehiko Yamazaki
  • Publication number: 20150273017
    Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.
    Type: Application
    Filed: October 24, 2013
    Publication date: October 1, 2015
    Inventors: Katsuto Tamai, Sokichi Kamata, Yasufumi Kaneda, Shigeru Miyagawa, Yoshiki Sawa, Takehiko Yamazaki
  • Publication number: 20150274792
    Abstract: Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord.
    Type: Application
    Filed: October 24, 2013
    Publication date: October 1, 2015
    Inventors: Katsuto Tamai, Takehiko Yamazaki, Wenhao Cui